Silence Therapeutics plc (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Silence Therapeutics plc (NASDAQ:SLN) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $40.67.

Several brokerages have weighed in on SLN. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Morgan Stanley cut their price target on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Wednesday, January 29th. William Blair reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, The Goldman Sachs Group lowered their target price on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research note on Tuesday.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new position in Silence Therapeutics in the 4th quarter valued at about $26,000. GAMMA Investing LLC lifted its stake in Silence Therapeutics by 609.2% in the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after purchasing an additional 5,233 shares in the last quarter. Barclays PLC lifted its stake in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after purchasing an additional 2,793 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Silence Therapeutics in the 4th quarter worth approximately $69,000. Finally, Virtus ETF Advisers LLC lifted its stake in Silence Therapeutics by 130.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after purchasing an additional 6,098 shares in the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Stock Performance

Shares of SLN opened at $4.73 on Thursday. The business’s 50-day moving average is $5.49 and its two-hundred day moving average is $11.53. The company has a market capitalization of $141.57 million, a P/E ratio of -3.01 and a beta of 1.05. Silence Therapeutics has a fifty-two week low of $4.06 and a fifty-two week high of $27.72.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.